Home > Publications database > CRL4DCAF1 ubiquitin ligase regulates PLK4 protein levels to prevent premature centriole duplication. > print

001     289013
005     20240425122524.0
024 7 _ |a 10.26508/lsa.202402668
|2 doi
024 7 _ |a pmid:38490717
|2 pmid
024 7 _ |a pmc:PMC10942865
|2 pmc
024 7 _ |a altmetric:160800241
|2 altmetric
037 _ _ |a DKFZ-2024-00545
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Grossmann, Josina
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a CRL4DCAF1 ubiquitin ligase regulates PLK4 protein levels to prevent premature centriole duplication.
260 _ _ |a Heidelberg
|c 2024
|b EMBO Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712309448_11099
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F045#LA:F045# / NEU/ #EA:D345#LA:D345#
520 _ _ |a Centrioles play important roles in the assembly of centrosomes and cilia. Centriole duplication occurs once per cell cycle and is dependent on polo-like kinase 4 (PLK4). To prevent centriole amplification, which is a hallmark of cancer, PLK4 protein levels need to be tightly regulated. Here, we show that the Cullin4A/B-DDB1-DCAF1, CRL4DCAF1, E3 ligase targets PLK4 for degradation in human cells. DCAF1 binds and ubiquitylates PLK4 in the G2 phase to prevent premature centriole duplication in mitosis. In contrast to the regulation of PLK4 by SCFβ-TrCP, the interaction between PLK4 and DCAF1 is independent of PLK4 kinase activity and mediated by polo-boxes 1 and 2 of PLK4, suggesting that DCAF1 promotes PLK4 ubiquitylation independently of β-TrCP. Thus, the SCFSlimb/β-TrCP pathway, targeting PLK4 for ubiquitylation based on its phosphorylation state and CRL4DCAF1, which ubiquitylates PLK4 by binding to the conserved PB1-PB2 domain, appear to be complementary ways to control PLK4 abundance to prevent centriole overduplication.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Kratz, Anne-Sophie
|0 P:(DE-He78)11bfb09146a8b8651ea33cdad7ec73c4
|b 1
700 1 _ |a Kordonsky, Alina
|b 2
700 1 _ |a Prag, Gali
|0 0000-0003-4703-7161
|b 3
700 1 _ |a Hoffmann, Ingrid
|0 P:(DE-He78)b97fa0c782a162d952b6197f3b916379
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.26508/lsa.202402668
|g Vol. 7, no. 6, p. e202402668 -
|0 PERI:(DE-600)2948687-7
|n 6
|p e202402668 -
|t Life science alliance
|v 7
|y 2024
|x 2575-1077
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289013
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)11bfb09146a8b8651ea33cdad7ec73c4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)b97fa0c782a162d952b6197f3b916379
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LIFE SCI ALLIANCE : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-02-08T19:01:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-02-08T19:01:09Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-02-08T19:01:09Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-02-08T19:01:09Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
920 2 _ |0 I:(DE-He78)F045-20160331
|k F045
|l Zellzykluskontrolle und Carcinogenese
|x 0
920 1 _ |0 I:(DE-He78)F045-20160331
|k F045
|l Zellzykluskontrolle und Carcinogenese
|x 0
920 1 _ |0 I:(DE-He78)D345-20160331
|k D345
|l Zellzykluskontrolle und Carcinogenese
|x 1
920 0 _ |0 I:(DE-He78)F045-20160331
|k F045
|l Zellzykluskontrolle und Carcinogenese
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F045-20160331
980 _ _ |a I:(DE-He78)D345-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21